Aetion

Senior Director of Research+Analytics

New York, New York, United States

Aetion Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Healthcare Analytics, Biotechnology, PharmaceuticalsIndustries

Requirements

The Senior Director of Research+Analytics requires a strong background in biostatistics and/or epidemiologic methods applied to real-world data, including expertise in R programming and experience managing teams of R programmers. Candidates should possess experience in data management, interpretation of results, and drafting or reviewing sections relevant to methods or results for reports or manuscripts.

Responsibilities

As a Senior Director, the candidate will directly and matrixed manage a team of R programmers to deliver robust analyses for Aetion’s real-world study portfolio, ensuring rigorous code strategy, code review, and quality control. They will serve as an internal expert in statistical and epidemiologic methods, supporting study design and conduct, autonomously conduct R programming, and contribute to methodological research projects. Furthermore, the role involves providing input on analytic product features, supporting their testing, and engaging in external thought leadership through presentations and publications.

Skills

Biostatistics
Epidemiologic methods
Real-world data analysis
R programming
Team management
Applied research

Aetion

Software solutions for real-world evidence analysis

About Aetion

Aetion develops software solutions that utilize real-world evidence (RWE) to assist life sciences companies, regulators, and purchasers in making informed decisions. Their software analyzes real-world data to provide insights into the effectiveness and safety of medical innovations, from initial hypotheses to long-term monitoring. Aetion's clients include major pharmaceutical companies and healthcare regulators, who benefit from the ability to generate and analyze diverse data sets for clinical insights that were previously hard to obtain. The company differentiates itself by offering a platform that not only manages longitudinal data but also generates synthetic health data using artificial intelligence. Aetion's goal is to maximize the return on investment for its clients by providing rapid insights that facilitate critical decision-making, ultimately expediting patient care and treatment options.

Key Metrics

New York City, New YorkHeadquarters
2012Year Founded
$198MTotal Funding
SERIES_CCompany Stage
AI & Machine Learning, HealthcareIndustries
201-500Employees

Benefits

Medical, dental, & vision insurance
Free membership to OneMedical
FSA
4% 401(k) match
Commuter benefits for parking & transit
Unlimited PTO
Paid parental leave
Wellness stipend
Company activities

Risks

Emerging RWE tech companies pose a threat to Aetion's market share.
Rapid AI advancements may require Aetion to invest heavily in R&D.
Potential EU data privacy law changes could impact Aetion's operations and compliance costs.

Differentiation

Aetion's RWE platform offers real-time collaboration with biopharma and medical device companies.
The company utilizes patented rapid-cycle analytics technology for effective medical treatment insights.
Aetion's software generates synthetic health data using AI for longitudinal data management.

Upsides

Aetion's Barcelona tech hub expansion enhances RWE technology with European talent.
Ken Watson's appointment as CTO is set to drive strategic growth and innovation.
Partnerships like with Intuitive and FDA boost trust in Aetion's regulatory data validation.

Land your dream remote job 3x faster with AI